Document Classification

Section Type: METHODS

Text: One hundred sixty-nine patients, 18 years of age or older, with histologically or cytologically proven, advanced, nonresectable NSCLC ; a Karnofsky performance status score of 50 or greater ; and no previous therapy were treated as follows : treatment arm 1 : hyperfractionated radiation therapy (HFX RT) to a total tumor dose of 64. 80 Gy (61 patients) ; treatment arm 2 : HFX RT to the same tumor dose with chemotherapy (CT) consisting of 100 mg of carboplatin, days 1 and 2, and 100 mg of etoposide (VP-16), days 1-3, given every week during the RT course (52 patients) ; and treatment arm 3 : HFX RT to the same tumor dose with CT consisting of 200 mg of CBCDA, days 1 and 2, and 100 mg of VP-16, days 1-5, during the first, third, and fifth weeks of the RT course (56 patients).